Straits Times Index
3,296.28 +23.56 (+0.72%) Nikkei
38,288.66 +736.50 (+1.96%) Hang Seng
17,010.95 +182.02 (+1.08%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,663.79 -234.44 (-0.35%) CMC Crypto 200
1,435.58 +20.82 (+1.47%)
Progressive Care, Inc. (RXMD)
| Previous close | 1.9200 |
| Open | 1.8500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.7780 - 1.8500 |
| 52-week range | 0.4000 - 6.0500 |
| Volume | |
| Avg. volume | 2,645 |
| Market cap | 11.233M |
| Beta (5Y monthly) | -0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6100 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNextPlat Announces Proposed Business Combination with Progressive Care Inc.
NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has entered into a definitive business combination agreement with its majority owned subsidiary, Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care").
- PR Newswire
NextPlat Reports Consolidated Year-End 2023 Results with Increased Revenues of $37.8 Million, Record Annual Margins of 30% and $26.3 Million in Cash
NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the financial results for the fiscal year-ended December 31, 2023 which consolidates the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care").
PR NewswireProgressive Care Inc. Announces Record Full Year 2023 Results with Revenues of $49.7 Million, an Increase of 22% with Annual Gross Margins of 30%
Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced financial results for the year ended December 31, 2023. The Company reported record annual revenues of approximately $49.7 million, a 22% increase from results reported for the year ended December 31, 2022, driven by strong growth at its PharmcoRx pharmacies and the addition of multiple new 340B contracts in the second half of 2023.
